(旧版)科学的根拠に基づく糖尿病診療ガイドライン 改訂第2版
2.糖尿病治療の目標と指針
文献
1) | 島 健二,遠藤治郎,老籾宗忠,他.グリコヘモグロビンの標準化に関する委員会報告(5).糖尿病.1998;41(4):317-23. |
2) | 葛谷 健,中川昌一,佐藤 譲,金澤康徳,岩本安彦,小林 正,南條輝志男,佐々木陽,清野 裕,伊藤千賀子,島 健二,野中共平,門脇 孝,糖尿病診断基準検討委員会.糖尿病の分類と診断基準に関する委員会報告.糖尿病.1999;42(5):385-404. |
3) | 伊藤千賀子.解説資料-2.血糖値とヘモグロビン(Hb)A1cについて.「老人保健事業における糖尿病及び循環器疾患の指導区分に関する検討」.日本公衆衛生協会.東京.2002;46-9. |
4) | Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-17. レベル2 |
5) | Ito C, Maeda R, Ishida S, Sasaki H, Harada H. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract. 2000;50(3):225-30. レベル4 |
6) | Ito C, Maeda R, Ishida S, Harada H, Inoue N, Sasaki H. Importance of OGTT for diagnosing diabetes mellitus based on prevalence and incidence of retinopathy. Diabetes Res Clin Pract. 2000;49(2-3):181-6. レベル4 |
7) | The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-86. レベル1 |
8) | American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26 Suppl 1:S33-50. |
9) | Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25(2):330-6. レベル1 |
10) | The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45(10):1289-98. レベル1 |
11) | Yoshida Y, Hagura R, Hara Y, Sugasawa G, Akanuma Y. Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2001;51(3):195-203. レベル4 |
12) | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53. レベル1 |
13) | Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyörälä K; DECODE Study Group; European Diabetes Epidemiology Group. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia. 2004;47(12):2118-28. Epub 2004 Dec 15. レベル1 |
14) | 赤沼安夫.宿題報告2-糖尿病の病態と治療.日本内科学会雑誌.1999;88:27-38. レベル4 |
15) | 清原 裕.地域住民中の糖尿病者における循環器疾患発症とその危険因子の関連 久山町研究.糖尿病合併症.2000;14(2):80-4. レベル1 |
16) | Tominaga M, Makino H, Yoshino G, Kuwa K, Takei I, Aono Y, Hoshino T, Umemoto M, Shimatsu A, Sanke T, Kuwashima M, Taminato T, Ono J. Japanese standard reference material for JDS Lot 2 haemoglobin A1c. I: Comparison of Japan Diabetes Society-assigned values to those obtained by the Japanese and USA domestic standardization programmes and by the International Federation of Clinical Chemistry reference laboratories. Ann Clin Biochem. 2005;42(Pt 1):41-6. (註:2007年4月現在,HbA1c測定用標準物質はこの論文のJDS Lot2からJCCLS CRM-004に変更されており,さらなる換算が必要となっている) |
17) | Groche D, Hoeno W, Hoss G, Vogt B, Herrmann Z, Witzigmann A. Standardization of two immunological HbA1c routine assays according to the new IFCC reference method. Clin Lab. 2003;49(11-12):657-61. |
18) | Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y; Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18(3):896-903. Epub 2007 Jan 31. レベル3 |